Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma

被引：61
|
作者：
Carlucci, Giuseppe [1 ]
Carney, Brandon [1 ,2 ,3 ]
Brand, Christian [1 ]
Kossatz, Susanne [1 ]
Irwin, Christopher P. [1 ]
Carlin, Sean D. [1 ]
Keliher, Edmund J. [4 ]
Weber, Wolfgang [1 ,5 ]
Reiner, Thomas [1 ,5 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA
[2] CUNY Hunter Coll, Dept Chem & Biochem, New York, NY 10065 USA
[3] CUNY, Grad Ctr, PhD Program Chem, New York, NY 10018 USA
[4] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA
[5] Weill Cornell Med Coll, New York, NY 10065 USA
来源：
MOLECULAR IMAGING AND BIOLOGY | 2015年 / 17卷 / 06期
基金：
美国国家科学基金会;
关键词：
PARP1; Glioblastoma; PET; Fluorescence; Multimodality; Imaging; U87; MG; IN-VIVO PET; OVARIAN-CANCER; SINGLE-CELL; ACID; INHIBITOR; RESECTION; OLAPARIB; DEFLUORINATION; EXCHANGE; THERAPY;
D O I：
10.1007/s11307-015-0858-0
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The current study presents [F-18]PARPi-FL as a bimodal fluorescent/positron emission tomography (PET) agent for PARP1 imaging. [F-18]PARPi-FL was obtained by F-19/F-18 isotopic exchange and PET experiments, biodistribution studies, surface fluorescence imaging, and autoradiography carried out in a U87 MG glioblastoma mouse model. [F-18]PARPi-FL showed high tumor uptake in vivo and ex vivo in small xenografts (< 2 mm) with both PET and optical imaging technologies. Uptake of [F-18]PARPi-FL in blocked U87 MG tumors was reduced by 84 % (0.12 +/- 0.02 %injected dose/gram (%ID/g)), showing high specificity of the binding. PET imaging showed accumulation in the tumor (1 h p.i.), which was confirmed by ex vivo phosphor autoradiography. The fluorescent component of [F-18]PARPi-FL enables cellular resolution optical imaging, while the radiolabeled component of [F-18]PARPi-FL allows whole-body deep-tissue imaging of malignant growth.
引用
收藏
页码：848 / 855
页数：8
相关论文
共 50 条
  • [31] Ultrasound/photoacoustic dual-modality imaging based on acoustic scanning galvanometer
    Xu Shou-Zhen
    Xie Shi-Meng
    Wu Dan
    Chi Zi-Hui
    Huang Lin
    ACTA PHYSICA SINICA, 2022, 71 (05)
  • [32] Fusion imaging in nuclear medicine - Applications of dual-modality systems in oncology
    Schillaci, O
    Simonetti, G
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (01) : 1 - 10
  • [33] Dual-modality optical diagnosis for precise in vivo identification of tumors in neurosurgery
    Zhu, Mingyu
    Chang, Wei
    Jing, Linkai
    Fan, Yingwei
    Liang, Ping
    Zhang, Xinran
    Wang, Guihuai
    Liao, Hongen
    THERANOSTICS, 2019, 9 (10): : 2827 - 2842
  • [34] Upconversion Nanoparticles Conjugated with Gd3+-DOTA and RGD for Targeted Dual-Modality Imaging of Brain Tumor Xenografts
    Jin, Jiefu
    Xu, Zhenhua
    Zhang, Yue
    Gu, Yan-Juan
    Lam, Michael Hon-Wah
    Wong, Wing-Tak
    ADVANCED HEALTHCARE MATERIALS, 2013, 2 (11) : 1501 - 1512
  • [35] Gadolinium-Based CuInS2/ZnS Nanoprobe for Dual-Modality Magnetic Resonance/Optical Imaging
    Cheng, Chun-Yi
    Ou, Keng-Liang
    Huang, Wei-Ting
    Chen, Jem-Kun
    Chang, Jia-Yaw
    Yang, Cheng-Hsien
    ACS APPLIED MATERIALS & INTERFACES, 2013, 5 (10) : 4389 - 4400
  • [36] Dual-modality imaging of atherosclerotic plaques using ultrasmall superparamagnetic iron oxide labeled with rhodamine
    Li, Yi
    Pan, Yutao
    Wu, Xiaodong
    Li, Yuan
    Wang, Huoqiang
    Zhu, Hong
    Jiang, Lei
    NANOMEDICINE, 2019, 14 (15) : 1935 - 1944
  • [37] Photonic crystal fiber-based dual-modality probe for simultaneous sensing and imaging applications
    Vengalathunadakal, Shinoj Kuttinarayanan
    Murukeshan, Vadakke M.
    Padmanabhan, Saraswathi
    Padmanabhan, Parasuraman
    OPTICAL ENGINEERING, 2009, 48 (10)
  • [38] Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
    Dehdashti, Farrokh
    Reimers, Melissa A.
    Shoghi, Kooresh, I
    Chen, Delphine L.
    Luo, Jingqin
    Rogers, Buck
    Pachynski, Russell K.
    Sreekumar, Sreeja
    Weimholt, Cody
    Zhou, Dong
    MOLECULAR IMAGING AND BIOLOGY, 2022, 24 (06) : 853 - 861
  • [39] Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
    Farrokh Dehdashti
    Melissa A. Reimers
    Kooresh I. Shoghi
    Delphine L. Chen
    Jingqin Luo
    Buck Rogers
    Russell K. Pachynski
    Sreeja Sreekumar
    Cody Weimholt
    Dong Zhou
    Molecular Imaging and Biology, 2022, 24 : 853 - 861
  • [40] Radiolabeled Iron Oxide Nanoparticles As Dual-Modality SPECT/MRI and PET/MRI Agents
    Bouziotis, Penelope
    Psimadas, Dimitrios
    Tsotakos, Theodoros
    Stamopoulos, Dimosthenis
    Tsoukalas, Charalampos
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (23) : 2694 - 2702
12345